Nomic Bio Secures $42M in Series B Funding to Revolutionize Protein Analysis

We are thrilled to announce that Nomic Bio, previously known as nplex biosciences, has successfully raised $42 million in its latest funding round. This significant investment demonstrates confidence in our mission to democratize access to the human proteome, making it as straightforward and widely accessible as the human genome. At Nomic, we are pioneering the next generation of enzyme-linked immunosorbent assay technology with our innovative nELISA platform. This cutting-edge solution enables researchers to measure proteins at scale and with high throughput, serving as a vital tool in drug discovery and biomarker development workflows. Our nELISA platform integrates seamlessly into existing laboratory practices, ensuring that scientists can easily adopt this technology to enhance their research. The funds raised will primarily be allocated toward accelerating the development and commercialization of the nELISA, as well as expanding our footprint in Montreal and Boston. This investment will also allow us to strengthen our team and further our commitment to advancing proteomic research, ultimately contributing to breakthroughs in personalized medicine. We are excited about the journey ahead and grateful for the continued support from our investors and partners. Together, we are poised to transform the way proteins are measured and harness the vast potential of the human proteome for therapeutic advancements. For more information about Nomic Bio and our groundbreaking work, please visit www.nomic.bio.